Credit Suisse Reiterates “Neutral” Rating for GVC Holdings Plc (LON:GVC) Stock; National Asset Management Lowered By $423,373 Its Gilead Sciences (GILD) Stake

GVC Holdings PLC (LON:GVC) Logo

National Asset Management Inc decreased Gilead Sciences Inc (GILD) stake by 24.59% reported in 2017Q4 SEC filing. National Asset Management Inc sold 5,963 shares as Gilead Sciences Inc (GILD)’s stock rose 1.93%. The National Asset Management Inc holds 18,289 shares with $1.31M value, down from 24,252 last quarter. Gilead Sciences Inc now has $96.30B valuation. The stock decreased 0.05% or $0.04 during the last trading session, reaching $73.86. About 4.25 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since April 30, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Today, Credit Suisse reiterated their “Neutral” rating on GVC Holdings Plc (LON:GVC)‘s stock in a report revealed.

Among 15 analysts covering Gvc Holdings (LON:GVC), 13 have Buy rating, 0 Sell and 2 Hold. Therefore 87% are positive. Gvc Holdings has GBX 1300 highest and GBX 484 lowest target. GBX 935.87’s average target is 4.39% above currents GBX 896.5 stock price. Gvc Holdings had 87 analyst reports since October 8, 2015 according to SRatingsIntel. The stock of GVC Holdings PLC (LON:GVC) earned “Buy” rating by Peel Hunt on Thursday, October 12. As per Monday, February 26, the company rating was maintained by Peel Hunt. The stock of GVC Holdings PLC (LON:GVC) earned “Buy” rating by Goodbody on Monday, April 25. Canaccord Genuity maintained it with “Buy” rating and GBX 1010 target in Friday, November 3 report. Citigroup upgraded it to “Buy” rating and GBX 1090 target in Friday, December 8 report. Canaccord Genuity maintained the stock with “Buy” rating in Monday, May 23 report. Citigroup maintained the stock with “Neutral” rating in Friday, March 24 report. Numis Securities maintained the shares of GVC in report on Thursday, July 6 with “Buy” rating. The firm earned “Buy” rating on Friday, March 9 by Peel Hunt. The firm has “Buy” rating by Liberum Capital given on Thursday, December 15.

GVC Holdings PLC, together with its subsidiaries, operates as an online gaming firm in Germany, the United Kingdom, Turkey, and internationally. The company has market cap of 5.16 billion GBP. It operates through five divisions: Sports Labels, Gaming Labels, B2B, Non-core, and Corporate. It currently has negative earnings. The firm offers sports betting, casinos, games, and poker through online and mobile under the Sportingbet brand; and online bingo, sportsbook, casino, and poker access under the Betboo brand, as well as operates an online casino Website for German-speaking markets under the CasinoClub brand.

The stock decreased 0.39% or GBX 3.5 during the last trading session, reaching GBX 896.5. About 409,320 shares traded. GVC Holdings PLC (LON:GVC) has 0.00% since April 30, 2017 and is . It has underperformed by 11.55% the S&P500.

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.23, from 1.03 in 2017Q3. It fall, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Sg Americas Secs Ltd Limited Liability Company holds 0.09% or 140,856 shares in its portfolio. Rhenman Ptnrs Asset Ab holds 2.77% or 285,751 shares. Greatmark Inv Ptnrs Inc reported 2.01% stake. Boston Prtn reported 7.77M shares or 0.66% of all its holdings. Bancorporation Of The West owns 84,581 shares. Argent Mgmt Ltd Co has 0.56% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Sigma Planning Corp has invested 0.17% in Gilead Sciences, Inc. (NASDAQ:GILD). Amer Beacon Advsrs Incorporated invested in 2,671 shares. 48,479 are owned by Arga Inv Mngmt Lp. Ariel Investments Limited Com reported 2.24 million shares. Permit Ltd Liability Com invested 1.3% in Gilead Sciences, Inc. (NASDAQ:GILD). Brandes Investment Prtn LP reported 65,796 shares stake. Hollencrest Capital Mgmt holds 0.03% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 3,223 shares. Mitchell Mcleod Pugh Williams reported 0.56% stake. Zwj Counsel owns 245,731 shares for 1.39% of their portfolio.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 126 analyst reports since July 29, 2015 according to SRatingsIntel. Atlantic Securities initiated the shares of GILD in report on Friday, December 18 with “Neutral” rating. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, February 3 report. Credit Suisse maintained the stock with “Outperform” rating in Wednesday, February 3 report. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Monday, February 12 by Mizuho. The firm has “Hold” rating by Oppenheimer given on Thursday, December 21. The firm has “Outperform” rating given on Wednesday, February 3 by Oppenheimer. As per Wednesday, October 5, the company rating was maintained by Jefferies. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Outperform” rating given on Wednesday, March 23 by Credit Suisse. The firm has “Hold” rating by Jefferies given on Tuesday, March 15. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Wednesday, June 1 by Gabelli.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on May, 1 after the close. They expect $1.59 earnings per share, down 27.73% or $0.61 from last year’s $2.2 per share. GILD’s profit will be $2.07B for 11.61 P/E if the $1.59 EPS becomes a reality. After $1.60 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -0.63% negative EPS growth.

Since January 2, 2018, it had 0 insider buys, and 19 selling transactions for $40.38 million activity. $3.68M worth of stock was sold by MARTIN JOHN C on Tuesday, January 2. $2.09 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Alton Gregg H on Thursday, February 1. On Friday, March 16 Cogan John Francis sold $467,138 worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 5,833 shares. $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by Washington Robin L. Shares for $8.02M were sold by Meyers James R on Tuesday, January 16. $4.68 million worth of stock was sold by WILSON GAYLE E on Friday, February 9.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart